CTCs May Predict Breast Cancer Recurrence

Area of Science:

• Oncology
• Cancer Research
• Molecular Diagnostics

Background:

• Estrogen receptor-positive, HER2-negative breast cancer is the most common subtype.
• Late recurrence of breast cancer can occur many years after initial diagnosis and treatment.
• Identifying biomarkers for predicting late recurrence is crucial for patient management.

Purpose of the Study:

• To investigate the prognostic significance of circulating tumor cells (CTCs) in patients with ER-positive, HER2-negative breast cancer.
• To determine the association between the presence of CTCs and the risk of late breast cancer recurrence.

Main Methods:

• Prospective study design.
• Long-term follow-up of patients with early-stage ER-positive, HER2-negative breast cancer.
• Detection of circulating tumor cells (CTCs) in peripheral blood samples several years post-treatment.

Main Results:

• The presence of CTCs several years after diagnosis was associated with a significantly increased risk of late breast cancer reappearance.
• Patients with detectable CTCs experienced a nearly 22-fold higher risk of late recurrence compared to those without CTCs.

Conclusions:

• Circulating tumor cells are a strong independent predictor of late recurrence in ER-positive, HER2-negative breast cancer.
• Long-term surveillance for CTCs may help identify patients at high risk for late disease reappearance.
• These findings underscore the need for continued monitoring and potential therapeutic strategies for patients with detectable CTCs.